BR0316223A - Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo - Google Patents

Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo

Info

Publication number
BR0316223A
BR0316223A BR0316223-0A BR0316223A BR0316223A BR 0316223 A BR0316223 A BR 0316223A BR 0316223 A BR0316223 A BR 0316223A BR 0316223 A BR0316223 A BR 0316223A
Authority
BR
Brazil
Prior art keywords
sepsis
onset
patient
prognosis
diagnosis
Prior art date
Application number
BR0316223-0A
Other languages
English (en)
Inventor
Richard Ivey
Thomas Gentle
Richard Moore
Michael Towns
Nicholas Bachur
Robert Rosenstein
Paul Goldenbaum
Song Shi
Donald Copertino
James Garrett
Gregory Tice
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of BR0316223A publication Critical patent/BR0316223A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODOS PARA DETERMINAR O ESTADO DE SEPSIA, PARA PROGNOSTICAR O COMEçO DE SEPSIA E PARA DIAGNOSTICAR A SìNDROME DE RESPOSTA INFLAMATóRIA SISTêMICA EM UM INDIVìDUO". O prognóstico ou diagnóstico prematuros da sepsia leva em conta vantajosamente a intervenção clínica antes que doença progrida rapidamente além dos estágios iniciais para estágios mais graves, tais como a sepsia severa ou o choque séptico, os quais se acham associados com a alta mortalidade. O prognóstico ou diagnóstico prematuros são realizados usando-se uma abordagem de diagnósticos moleculares, envolvendo a comparação de um perfil de expressão biomarcadora do paciente, com os perfis obtidos de uma ou mais populações de controle, ou de referência, as quais podem incluir uma população que desenvolva a sepsia. O reconhecimento dos aspectos no perfil biomarcador do paciente, que sejam característicos do começo de sepsia, permite a um clínico diagnosticar o início da sepsia de um fluido corporal isolado no paciente em um ponto único no tempo. A necessidade de monitorar o paciente durante um período de tempo é, portanto, vantajosamente evitada, possibilitando a intervenção clínica antes do começo dos sintomas sérios da sepsia.
BR0316223-0A 2002-11-12 2003-11-12 Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo BR0316223A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42532202P 2002-11-12 2002-11-12
PCT/US2003/036021 WO2004044556A2 (en) 2002-11-12 2003-11-12 Diagnosis of sepsis or sirs using biomarker profiles

Publications (1)

Publication Number Publication Date
BR0316223A true BR0316223A (pt) 2005-10-04

Family

ID=32312968

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0316197-8A BR0316197A (pt) 2002-11-12 2003-11-12 Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro
BR0316223-0A BR0316223A (pt) 2002-11-12 2003-11-12 Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0316197-8A BR0316197A (pt) 2002-11-12 2003-11-12 Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro

Country Status (9)

Country Link
US (2) US20040097460A1 (pt)
EP (2) EP1590469A4 (pt)
JP (2) JP2006506070A (pt)
CN (4) CN1742087A (pt)
AU (2) AU2003291488A1 (pt)
BR (2) BR0316197A (pt)
CA (2) CA2505785A1 (pt)
MX (2) MXPA05005072A (pt)
WO (2) WO2004043236A2 (pt)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758503B2 (en) * 1997-01-27 2010-07-20 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
US8932227B2 (en) * 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US20060161071A1 (en) 1997-01-27 2006-07-20 Lynn Lawrence A Time series objectification system and method
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US20070191697A1 (en) 2006-02-10 2007-08-16 Lynn Lawrence A System and method for SPO2 instability detection and quantification
US20080287756A1 (en) * 1997-07-14 2008-11-20 Lynn Lawrence A Pulse oximetry relational alarm system for early recognition of instability and catastrophic occurrences
US20050060101A1 (en) * 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US20060195041A1 (en) 2002-05-17 2006-08-31 Lynn Lawrence A Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US20070093721A1 (en) * 2001-05-17 2007-04-26 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
CA2505902A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
MXPA05005031A (es) 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
CN1742087A (zh) * 2002-11-12 2006-03-01 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
US20080070235A1 (en) * 2003-04-02 2008-03-20 Sirs-Lab Gmbh Method for Recognizing Acute Generalized Inflammatory Conditions (Sirs), Sepsis, Sepsis-Like Conditions and Systemic Infections
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2005033327A2 (en) * 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
EP1677735B1 (en) 2003-10-17 2014-07-23 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
DE102004009952B4 (de) * 2004-03-01 2011-06-01 Sirs-Lab Gmbh Verfahren zur Erkennung von Sepsis
DE102004015605B4 (de) * 2004-03-30 2012-04-26 Sirs-Lab Gmbh Verfahren zur Vorhersage des individuellen Krankheitsverlaufs bei Sepsis
JP4441603B2 (ja) * 2004-07-13 2010-03-31 株式会社エヌ・ティ・ティ・データ リスク評価装置、及び、プログラム
DE102004049897B4 (de) 2004-10-13 2007-11-22 Sirs-Lab Gmbh Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens
WO2007011412A2 (en) * 2004-11-05 2007-01-25 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Diagnosis and prognosis of infectious diesease clinical phenotypes and other physiologic states using host gene expresion biomarkers in blood
GB0426982D0 (en) * 2004-12-09 2005-01-12 Secr Defence Early detection of sepsis
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
FR2881437B1 (fr) * 2005-01-31 2010-11-19 Biomerieux Sa Procede pour le diagnostic/pronostic d'un syndrome septique
DE102005013013A1 (de) * 2005-03-21 2006-09-28 Sirs-Lab Gmbh Verwendung von Genaktivitäts-Klassifikatoren für die in vitro Klassifizierung von Genexpressionsprofilen von Patienten mit infektiösem/nichtinfektiösem Multiorganversagen
CA2603550A1 (en) * 2005-03-31 2006-10-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating neuropsychiatric disorders
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7481280B2 (en) * 2005-06-20 2009-01-27 1243939 Alberta Ltd. Method and apparatus for conducting earth borehole operations using coiled casing
AU2006269820B2 (en) 2005-07-07 2012-01-19 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
AU2006267097A1 (en) * 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
AU2006294481B2 (en) 2005-09-28 2012-12-20 Becton, Dickinson And Company Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
JP2009510478A (ja) * 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
WO2007048107A2 (en) * 2005-10-19 2007-04-26 Heska Corporation Proteomic profiling of mast cell tumors and related methods, proteins and nucleic acid molecules
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
DE602006015221D1 (de) * 2005-11-25 2010-08-12 Trinity College Dublin Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
WO2007078841A2 (en) * 2005-12-15 2007-07-12 Becton, Dickinson And Company Diagnosis of sepsis
US20070184460A1 (en) * 2006-02-09 2007-08-09 Wei-Mei Ching Diagnostic assay for Orientia tsutsugamushi by detection of responsive gene expression
US20110160075A1 (en) * 2006-02-09 2011-06-30 Wei-Mei Ching Diagnostic assay for orientia tsutsugamushi by detection of responsive gene expression
US7668579B2 (en) * 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
WO2007100913A2 (en) * 2006-02-28 2007-09-07 The Regents Of The University Of California Genes differentially expressed in bipolar disorder and/or schizophrenia
US20090220973A1 (en) * 2006-04-03 2009-09-03 Joslin Diabetes Center, Inc. Obesity and body fat distribution
GB0610078D0 (en) * 2006-05-20 2006-06-28 Secr Defence Sepsis detection microarray
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CN101743552B (zh) * 2007-07-13 2016-08-10 皇家飞利浦电子股份有限公司 用于急性动态疾病的决策支持系统
US8386184B2 (en) * 2007-08-28 2013-02-26 Becton, Dickinson And Company Systems and methods for determining an amount of starting reagent using the polymerase chain reaction
GB0722582D0 (en) * 2007-11-16 2007-12-27 Secr Defence Early detection of sepsis
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
US7776522B2 (en) * 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
AU2009244308A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
CA2722773C (en) 2008-05-07 2015-07-21 Lawrence A. Lynn Medical failure pattern search engine
US10943692B1 (en) * 2008-05-07 2021-03-09 Lawrence A. Lynn System and method for generating quaternary images of biologic force propagation and recovery
BRPI0913924B1 (pt) 2008-07-01 2020-02-04 Univ Leland Stanford Junior método para determinação da probabilidade de que um indivíduo do sexo feminino irá experimentar um evento de nascimento com vida
EP3301446B1 (en) * 2009-02-11 2020-04-15 Caris MPI, Inc. Molecular profiling of tumors
US20120135425A1 (en) * 2010-08-23 2012-05-31 The Ohio State University Research Foundation ELISA for Haptoglobin-Matrix Metalloproteinase 9 Complex as a Diagnostic Test for Conditions Including Acute Inflammation
US20130054264A1 (en) * 2011-03-04 2013-02-28 Sterling Point Research, Llc Systems and methods for optimizing medical care through data monitoring and feedback treatment
US11676730B2 (en) 2011-12-16 2023-06-13 Etiometry Inc. System and methods for transitioning patient care from signal based monitoring to risk based monitoring
US20130231949A1 (en) 2011-12-16 2013-09-05 Dimitar V. Baronov Systems and methods for transitioning patient care from signal-based monitoring to risk-based monitoring
CA2863393C (en) 2012-02-07 2022-04-26 Hector R. Wong A multi-biomarker-based outcome risk stratification model for pediatric septic shock
WO2013119869A1 (en) * 2012-02-07 2013-08-15 Children's Hospital Medical Center A multi-biomarker-based outcome risk stratification model for adult septic shock
CA2864526C (en) * 2012-02-14 2019-12-31 Purdue Pharma L.P. Systems and methods to quantify analytes in keratinized samples
US20150293131A1 (en) * 2012-04-02 2015-10-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
US9953453B2 (en) 2012-11-14 2018-04-24 Lawrence A. Lynn System for converting biologic particle density data into dynamic images
US10354429B2 (en) 2012-11-14 2019-07-16 Lawrence A. Lynn Patient storm tracker and visualization processor
WO2014134530A1 (en) * 2013-02-28 2014-09-04 Lynn Lawrence A Patient storm tracker and visualization processor
WO2014201516A2 (en) 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
WO2015077781A1 (en) 2013-11-25 2015-05-28 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
ES2661894T3 (es) * 2013-12-23 2018-04-04 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Procedimiento para detectar una inflamación sistémica y sistema de análisis
JP2017512304A (ja) * 2014-02-06 2017-05-18 イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ バイオマーカーシグネチャー法ならびにそのための装置およびキット
GB201402293D0 (en) * 2014-02-11 2014-03-26 Secr Defence Biomarker signatures for the prediction of onset of sepsis
GB201406259D0 (en) 2014-04-07 2014-05-21 Univ Edinburgh Molecular predictors of neonatal sepsis
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
US10261068B2 (en) 2015-06-04 2019-04-16 Children's Hospital Medical Center Persevere-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype
PL235777B1 (pl) 2015-07-10 2020-10-19 Univ Jagiellonski Startery, sposób i zestaw diagnostyczny do diagnozowania sepsy
US11884978B2 (en) 2015-09-30 2024-01-30 Immunexpress Pty Ltd Pathogen biomarkers and uses therefor
DK3371324T3 (da) * 2015-11-06 2021-11-15 Immunexpress Pty Ltd Virusbiomarkører og anvendelser deraf
CN115482925A (zh) 2016-01-28 2022-12-16 贝克曼考尔特公司 感染检测和区分系统及方法
GB201605110D0 (en) * 2016-03-24 2016-05-11 Mologic Ltd Detecting sepsis
AU2017289600A1 (en) 2016-06-26 2018-12-06 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for use in prognosis of mortality in critically ill patients
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
US11791022B2 (en) 2017-02-28 2023-10-17 Beckman Coulter, Inc. Cross discipline disease management system
WO2018229019A1 (en) * 2017-06-12 2018-12-20 Koninklijke Philips N.V. Risk assessment of disseminated intravascular coagulation
US11852640B2 (en) 2017-10-27 2023-12-26 Beckman Coulter, Inc. Hematology analyzers and methods of operation
US11521706B2 (en) 2018-04-20 2022-12-06 Beckman Coulter, Inc. Testing and representing suspicion of sepsis
US11538566B2 (en) 2018-05-23 2022-12-27 Beckman Coulter, Inc. Sample analysis with test determination based on identified condition
US11644464B2 (en) 2018-04-20 2023-05-09 Beckman Coulter, Inc. Sepsis infection determination systems and methods
CN111989032A (zh) * 2018-06-15 2020-11-24 拜克门寇尔特公司 存在母细胞标志时确定败血症的方法
CN109022572A (zh) * 2018-09-14 2018-12-18 北京泱深生物信息技术有限公司 作为脓毒症诊断标志物的loc101927627及其应用
CN109022571A (zh) * 2018-09-14 2018-12-18 北京泱深生物信息技术有限公司 Loc105369645作为脓毒症诊断标志物的用途
US11796447B2 (en) 2019-07-12 2023-10-24 Beckman Coulter, Inc. Systems and methods for using cell granularitry in evaluating immune response to infection
EP3882363A1 (en) * 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
EP4158352A1 (en) * 2020-06-01 2023-04-05 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
CN111721941B (zh) * 2020-07-17 2023-08-25 南方科技大学 一种用于判断脓毒症感染情况的装置及其应用
WO2022081786A1 (en) * 2020-10-14 2022-04-21 Lee, Matthew Methods and devices for early diagnosis and monitoring of sepsis
JP2024514404A (ja) * 2021-03-11 2024-04-02 コーニンクレッカ フィリップス エヌ ヴェ 高リスク敗血症患者のための予後経路
CN116304932B (zh) * 2023-05-19 2023-09-05 湖南工商大学 一种样本生成方法、装置、终端设备及介质

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1504597A1 (ru) 1986-06-25 1989-08-30 Актюбинский государственный медицинский институт Способ дифференциальной диагностики сепсиса и локализованной гнойной инфекции у новорожденных
AU1235392A (en) * 1991-01-14 1992-08-17 New York University Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
CA2512290C (en) 1993-05-28 2010-02-02 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
RU2072103C1 (ru) 1993-06-10 1997-01-20 Ростовский научно-исследовательский институт акушерства и педиатрии Способ диагностики бактериальных инфекций у новорожденных
US5484705A (en) 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US6190872B1 (en) * 1994-05-06 2001-02-20 Gus J. Slotman Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method
US5804370A (en) 1994-06-08 1998-09-08 Critichem Medical Products Limited Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
US6306614B1 (en) 1994-06-08 2001-10-23 Sepsis, Inc. Measurement of analytes in whole blood
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5780237A (en) * 1994-10-12 1998-07-14 Cell Therapeutics, Inc. Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5708591A (en) 1995-02-14 1998-01-13 Akzo Nobel N.V. Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions
US6429017B1 (en) 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US5830679A (en) * 1996-03-01 1998-11-03 New England Medical Center Hospitals, Inc. Diagnostic blood test to identify infants at risk for sepsis
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US6077665A (en) * 1996-05-07 2000-06-20 The Board Of Trustees Of The Leland Stanford Junior University Rapid assay for infection in neonates
WO1998001738A2 (en) 1996-06-20 1998-01-15 Cornell Research Foundation, Inc. Identification of abnormalities in the expression of t and b cell antigen receptors as disease indicators
US6172220B1 (en) * 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
IL135593A (en) 1997-10-14 2004-06-01 Luminex Corp Precisely fluorescently painted polymeric microspheres and methods for making and using them
EP1887014B1 (en) 1997-10-17 2010-04-07 Genentech, Inc. Human toll homologues
US6159683A (en) * 1997-12-16 2000-12-12 Spectral Diagnostics, Inc. Method of determining stage of sepsis
US6268222B1 (en) * 1998-01-22 2001-07-31 Luminex Corporation Microparticles attached to nanoparticles labeled with flourescent dye
US6592822B1 (en) * 1998-05-14 2003-07-15 Luminex Corporation Multi-analyte diagnostic system and computer implemented process for same
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
WO2000042222A2 (en) 1999-01-15 2000-07-20 Gene Logic Inc. Immobilized nucleic acid hybridization reagent and method
CA2362055C (en) 1999-02-04 2010-07-20 Akzo Nobel N.V. A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
EP1147224A1 (en) * 1999-02-05 2001-10-24 WRAIR (Walter Reed Army Institute of Research) Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20050060101A1 (en) 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US20040225449A1 (en) 1999-06-28 2004-11-11 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using selected gene expression profiles
DE10027113A1 (de) 1999-12-23 2001-09-27 Andreas Hoeft Verfahren zur Bestimmung von mikrobieller DNS/RNS, Kit dafür und Verwendung des Verfahrens
US6660482B1 (en) * 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
WO2001065257A2 (de) * 2000-03-03 2001-09-07 Gerd Schmitz Verfahren zur analyse von exogener und endogener zell-aktivierung
US7363165B2 (en) * 2000-05-04 2008-04-22 The Board Of Trustees Of The Leland Stanford Junior University Significance analysis of microarrays
DE60112949T2 (de) 2000-06-09 2006-05-18 Biomerieux, Inc. Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes
ES2609016T3 (es) * 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2415775A1 (en) * 2000-07-18 2002-01-24 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
JP2004536276A (ja) * 2000-11-16 2004-12-02 シファーゲン バイオシステムズ， インコーポレイテッド 質量スペクトルを分析する方法
JP2004522742A (ja) 2000-12-08 2004-07-29 ベイラー　カレッジ　オブ　メディシン 免疫応答の改変において使用するためのｔｒｅｍ−１スプライス改変体
EP1360336A2 (en) 2001-02-15 2003-11-12 Bayer Corporation Innate immunity markers for rapid diagnosis of infectious diseases
US20040121350A1 (en) 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040126767A1 (en) 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6627607B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
US20020160420A1 (en) 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
EP1270740A1 (en) 2001-06-29 2003-01-02 SIRS-Lab GmbH Biochip and its use for determining inflammation
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
WO2003021257A1 (en) * 2001-08-30 2003-03-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Of Pennsylvania Algorithm for estimating the outcome of inflammation following injury or infection
WO2003023839A1 (en) * 2001-09-12 2003-03-20 Mass Consortium Corporation High throughput chemical analysis by improved desorption/ionization on silicon mass spectrometry
US6939716B2 (en) * 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
DE10155600B4 (de) * 2001-11-09 2009-08-27 Oligene Gmbh Nukleinsäure-Array
EP1451340B1 (en) * 2001-11-09 2014-01-08 Life Technologies Corporation Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
ATE282831T1 (de) 2001-12-04 2004-12-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente
DE50105971D1 (de) 2001-12-04 2005-05-25 Brahms Ag Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125
EP1318404B1 (de) 2001-12-04 2004-07-28 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 19-9
DE50103030D1 (de) 2001-12-04 2004-09-02 Brahms Ag Verfahren zur Diagnose von Sepsis unter Bestimmung von S100B
US20040072237A1 (en) 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
US20040038201A1 (en) * 2002-01-22 2004-02-26 Whitehead Institute For Biomedical Research Diagnostic and therapeutic applications for biomarkers of infection
US7282368B2 (en) * 2002-02-27 2007-10-16 Biomerieux, Inc. Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
US7465555B2 (en) * 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
EP1355159A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verwendungen von Fragmenten der Carbamoylphosphat Synthetase 1 (CPS 1) für die Diagnose von Entzündungserkrankungen und Sepsis
EP1355158A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker
EP1369693A1 (de) * 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Sepsisdiagnose und zur Kontrolle von Spenderblut durch Bestimmung von anti-Asialo-Gangliosid-Antikörpern
US6920721B2 (en) * 2002-06-05 2005-07-26 Adv-Tech Building Systems, Llc Building system
US20040009503A1 (en) 2002-07-03 2004-01-15 Molecular Staging, Inc. Immune modulatory activity of human ribonucleases
CA2491026A1 (en) 2002-07-05 2004-01-15 The University Of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
AU2003242509A1 (en) 2002-07-11 2004-02-02 Upfront Chromatography A/S An extracorporeal stabilised expanded bed adsorption method for the treatment of sepsis
JP5179011B2 (ja) 2002-10-09 2013-04-10 ディーエムアイ バイオサイエンシズ インコーポレイテッド 胎盤虚血および多臓器不全のモニタリング
WO2004043223A2 (en) 2002-11-05 2004-05-27 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
CN1742087A (zh) * 2002-11-12 2006-03-01 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
CA2505902A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
MXPA05005031A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
EP1426447A1 (en) 2002-12-06 2004-06-09 Roche Diagnostics GmbH Method for the detection of pathogenic gram positive bacteria selected from the genera Staphylococcus, Enterococcus and Streptococcus
CA2507240C (en) 2002-12-06 2011-05-24 F. Hoffmann-La Roche Ag Multiplex assay detection of pathogenic organisms
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
US20080070235A1 (en) 2003-04-02 2008-03-20 Sirs-Lab Gmbh Method for Recognizing Acute Generalized Inflammatory Conditions (Sirs), Sepsis, Sepsis-Like Conditions and Systemic Infections
FR2855832B1 (fr) * 2003-06-03 2007-09-14 Biomerieux Sa Procede de diagnostic et/ou de pronostic d'un syndrome septique
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2005033327A2 (en) 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
WO2005064307A2 (en) 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20060024744A1 (en) * 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
EP1869463A4 (en) * 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS

Also Published As

Publication number Publication date
JP2006506069A (ja) 2006-02-23
MXPA05005072A (es) 2005-07-22
CN1742087A (zh) 2006-03-01
EP1590469A2 (en) 2005-11-02
CN1738909A (zh) 2006-02-22
CA2505843A1 (en) 2004-05-27
CN1738908A (zh) 2006-02-22
AU2003291484A1 (en) 2004-06-03
EP1575978A2 (en) 2005-09-21
WO2004043236A2 (en) 2004-05-27
WO2004043236A3 (en) 2005-07-28
CA2505785A1 (en) 2004-05-27
US20040106142A1 (en) 2004-06-03
MXPA05005071A (es) 2005-07-22
WO2004044556A2 (en) 2004-05-27
BR0316197A (pt) 2005-09-27
WO2004044556A3 (en) 2005-09-09
JP2006506070A (ja) 2006-02-23
US7645573B2 (en) 2010-01-12
CN1829730A (zh) 2006-09-06
EP1575978A4 (en) 2006-04-19
US20040097460A1 (en) 2004-05-20
AU2003291488A1 (en) 2004-06-03
EP1590469A4 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
BR0316223A (pt) Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo
BR0316232A (pt) Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo
BR0316231A (pt) Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit
Kahli et al. Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass
Simsek et al. Inflammatory mediators in the diagnosis and treatment of acute pancreatitis: pentraxin-3, procalcitonin and myeloperoxidase
Barcz et al. Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis
KR102266302B1 (ko) 심혈관 질환 또는 문제 위험 예측용 방법 및 키트
Sullivan et al. Major trauma and acceleration of the ageing process
RU2611891C1 (ru) Способ прогнозирования нежелательного клинического исхода у больных острым инфарктом миокарда
Martin et al. Intestinal resection induces angiogenesis within adapting intestinal villi
KR102373721B1 (ko) 다발성 골수종 치료
Rubiś et al. 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis
Wang et al. The epidemiology of atrial fibrillation
Norris et al. Non-invasive diagnosis of arterial patency after thrombolytic treatment and its relation to prognosis.
RU2817191C1 (ru) Способ прогнозирования улучшения диастолической функции левого желудочка через 6 месяцев после процедуры симпатической денервации почечных артерий у больных резистентной артериальной гипертонией в сочетании с сахарным диабетом 2-го типа
ES2336649T3 (es) Procedimiento de cribado de agentes susceptibles de tratar la obesidad.
Weyand et al. original work is properly cited.
Wong et al. 067 Metformin in insulin resistant LV dysfunction, a double-blind, placebo controlled trial (Tayside trial)
Ruzhanska et al. Galectin-3 as a marker of myocardial function in men aged 40-60 years without cardiovascular pathology, carriers of polymorphic genes at1r
Latif et al. PLATELET DISTRIBUTION WIDTH VALUE AS A DIAGNOSTIC AND PROGNOSTIC MARKER IN ACUTE CORONARY SYNDROME
Dey The expression of heart enriched transposable elements associated lncRNAs
Song et al. Increased SPARC expression in skeletal muscle and adipose tissue of db/db mice
Rusak et al. COMPARISON OF ENDOTHELIAL FUNCTION BY MEANS OF FLOW MEDIATED DILATION USING CAROTID-RADIAL PULSE WAVE VELOCITY IN HYPERTENSIVE SUBJECTS WITH AND WITHOUT TYPE II DIABETES
AR039967A1 (es) Diagnostico y tratamiento del glaucoma y metodos para descubrir nuevos agentes terapeuticos basandose en la via de senalizacion de wnt/ca2-
Parati Clinical relevance of masked hypertension

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.